Personalizing transfusion in sickle cell disease: where is the canary in the mine?
- PMID: 31374145
- DOI: 10.1111/trf.15453
Personalizing transfusion in sickle cell disease: where is the canary in the mine?
Comment on
-
Interval decline in hemoglobin A is associated with annual clinical event rate in sickle cell anemia patients receiving maintenance apheresis RBC exchange.Transfusion. 2019 Aug;59(8):2622-2628. doi: 10.1111/trf.15386. Epub 2019 Jun 3. Transfusion. 2019. PMID: 31161685 Clinical Trial.
References
REFERENCES
-
- Detterich JA. Simple chronic transfusion therapy, a crucial therapeutic option for sickle cell disease, improves but does not normalize blood rheology: what should be our goals for transfusion therapy? Clin Hemorheol Microcirc 2018;68:173-86.
-
- Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-94.
-
- Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 1992;326:605-10.
-
- Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
-
- Bernaudin F, Verlhac S, Arnaud C, et al. Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood 2015;125:1653-61.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
